Toward the conclusion of 2017, a team of seasoned industry professionals and researchers with extensive expertise in pharmaceutical research and innovation founded Accro Bioscience (Suzhou) Limited. Fully owned by Accro Bioscience (HK) Limited, Accro Bioscience (Suzhou) Limited is a biotechnology company in the clinical development phase, focused primarily on the molecular mechanisms of controlled cellular death and associated pathogenesis in human ailments. By leveraging scientific knowledge and drug exploration, the company has cultivated a strong collection of pioneering compounds at various stages, ranging from initial improvement to clinical trials.
Accro Bioscience
Headquarters
People's Republic of China